Stockscreener 앱 받기
1.6885
1.72%
0.0285
전일 마감가:
$1.66
열려 있는:
$1.67
하루 거래량:
39,749
Relative Volume:
0.17
시가총액:
$23.68M
수익:
$128.60K
순이익/손실:
$-4.60M
주가수익비율:
-2.6802
EPS:
-0.63
순현금흐름:
$-3.74M
1주 성능:
-3.51%
1개월 성능:
-28.76%
6개월 성능:
+27.92%
1년 성능:
+27.92%
1일 변동 폭
$1.6161
$1.75
1주일 범위
$1.56
$2.31
52주 변동 폭
$0.53
$4.4899
Nexalin Technology Inc Stock (NXL) Company Profile
명칭
Nexalin Technology Inc
전화
(832) 260-0222
주소
1776 YORKTOWN, HOUSTON
NXL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
1.6885 | 23.68M | 128.60K | -4.60M | -3.74M | -0.63 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Nexalin Technology Inc 주식(NXL)의 최신 뉴스
Nexalin Technology appoints new accounting firm - Investing.com
Nexalin secures patent on brain stimulation method for substance use disorders - Yahoo Finance
Nexalin Secures Patent for Intracranial Stimulation Technology - MarketScreener
Nexalin Technology Secures USPTO Patent for Deep - GlobeNewswire
Game-Changing Patent: Nexalin's Brain Stimulation Tech Takes On $35B Addiction Treatment Market - Stock Titan
Nexalin begins clinical trial for brain stimulation therapy By Investing.com - Investing.com South Africa
Nexalin begins clinical trial for brain stimulation therapy - Investing.com
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial - The Manila Times
Revolutionary Brain Treatment: Nexalin Launches PTSD Trial at UCSD with AI-Powered Home Therapy - Stock Titan
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3 - GlobeNewswire
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3 - The Manila Times
Revolutionary Brain Tech Targets $537B Market: Nexalin CEO Reveals Growth Strategy - Stock Titan
Nexalin Technology (NASDAQ:NXL) Upgraded to “Buy” at Maxim Group - Defense World
Nexalin Technology (NASDAQ:NXL) Upgraded at Maxim Group - The AM Reporter
Maxim Group Upgrades Nexalin Technology (NXL) - Nasdaq
Nexalin Technology, Inc. SEC 10-K Report - TradingView
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Weatherford Democrat
Nexalin Technology’s Senior VP Makes a Bold Stock Purchase - TipRanks
Nexalin technology’s Sr. VP Carolyn Shelton acquires $13,200 in stock - Investing.com India
Nexalin technology’s Sr. VP Carolyn Shelton acquires $13,200 in stock By Investing.com - Investing.com UK
Nexalin Technology Stock Price, Quotes and Forecasts | NASDAQ:NXL - Benzinga
Nexalin Technology, Inc. Receives USPTO Notice of Allowance for Patent on Innovative Treatment Method for Opioid and Substance Use Disorders - Nasdaq
Nexalin Technology Receives Notice of Allowance from the - GlobeNewswire
Could This Newly Patented Technology Transform How We Treat Addiction? - StockTitan
UCSD begins trial with Nexalin’s Halo Clarity device for mTBI and PTSD - Yahoo Finance
Nexalin Technology Announces Initiation of Patient - GlobeNewswire
Nexalin Technology, Inc. Launches Clinical Trial for HALO™ Clarity Device to Treat Mild Traumatic Brain Injury and PTSD at UCSD - Nasdaq
Nexalin Technology announces initiation of patient recruitment in UCSD study - TipRanks
Can Nexalin's Brain Stimulation Technology Transform PTSD Treatment? UCSD Trial Now Recruiting Patients - StockTitan
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board - EIN News
Nexalin Technology Appoints General Wesley Clark to Military & Government Advisory Board - citybiz
Can NATO's Former Supreme Commander Help Nexalin Crack the Military Mental Health Market? - StockTitan
Nexalin Secures UCSD IRB Approval For Use Of HALO Clarity In PTSD And MTBI Clinical Studies - Nasdaq
Nexalin Technology Announces UCSD IRB Approval for use of - GlobeNewswire
Nexalin Technology Announces UCSD IRB Approval For Use Of HALO Clarity In Clinical Trials For mTBI And PTSD Treatment - Marketscreener.com
Nexalin Technology Says Halo Clarity Headset Clinical Testing Gets UCSD Institutional Review Board Approval - Marketscreener.com
Nexalin Technology, Inc. Receives IRB Approval for UCSD Clinical Trials of HALO™ Clarity Headset in Treating mTBI and PTSD - Nasdaq
Revolutionary Brain Treatment Device Enters Military PTSD Trials at UCSDPotential Breakthrough for Veterans - StockTitan
10,000 Shares in Nexalin Technology, Inc. (NASDAQ:NXL) Bought by Kingsview Wealth Management LLC - Defense World
Nexalin Technology Inc [NASDAQ: NXL] Sees Decrease in Stock Value - Knox Daily
Nexalin technology's chief medical officer buys $3,100 in shares - MSN
Nexalin Technology Inc’s latest rating changes from various analysts - Knox Daily
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition - GlobeNewswire
Nexalin Technology, Inc. Appointed Industry Co-Chair of National Traumatic Brain Injury Registry Coalition - Nasdaq
Nexalin (NXL) Secures Leadership Role in $4.5B Brain Injury MarketKey Details Investors Should See - StockTitan
Nexalin Technology announces effective registration statement - MSN
Nexalin Technology announces effective registration statement By Investing.com - Investing.com UK
Nexalin Technology Inc (NXL) Stock: A Year of Highs and Lows - The InvestChronicle
Nexalin Technology Inc (NXL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Nexalin Technology Inc 주식 (NXL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Owens David | Chief Medical Officer |
Feb 04 '25 |
Buy |
3.10 |
1,000 |
3,100 |
155,793 |
| Owens David | Chief Medical Officer |
Feb 04 '25 |
Buy |
2.98 |
1,000 |
2,980 |
154,793 |
| Owens David | Chief Medical Officer |
Jan 28 '25 |
Buy |
2.70 |
1,500 |
4,050 |
153,793 |
| Owens David | Chief Medical Officer |
Jan 13 '25 |
Buy |
2.50 |
2,000 |
5,000 |
151,293 |
| Owens David | Chief Medical Officer |
Jan 23 '25 |
Buy |
2.70 |
1,000 |
2,700 |
152,293 |
| Owens David | Chief Medical Officer |
Oct 28 '24 |
Buy |
2.19 |
500 |
1,095 |
148,293 |
| Owens David | Chief Medical Officer |
Aug 13 '24 |
Buy |
0.95 |
1,000 |
950 |
147,793 |
| Owens David | Chief Medical Officer |
Jun 28 '24 |
Buy |
1.75 |
1,000 |
1,750 |
146,793 |
| Owens David | Chief Medical Officer |
Jun 18 '24 |
Buy |
0.71 |
1,619 |
1,149 |
145,793 |
| Owens David | Chief Medical Officer |
Jun 10 '24 |
Buy |
0.64 |
3,000 |
1,920 |
144,174 |
1.01%
0.46%
자본화:
|
볼륨(24시간):